Syngene International Ltd (SYNGENE) is currently trading at 381.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Syngene International Limited is a leading integrated research, development, and manufacturing organization serving sectors like pharmaceuticals, biotechnology, nutrition, and chemicals. Its two main segments, Research Services and Contract Development Manufacturing Services (CDMO), offer a wide range of capabilities across large and small molecules. The company’s strategic partnerships, particularly its extended relationship with Bristol Myers Squibb, underscore its robust collaborative framework, supporting its scientific and operational expansion until 2035. Significant challenges emerged with a notable decline due to the impact from a single large molecule biologics product, affecting short-term financial performance and leading to revised guidance of a 3–5% decline in annual revenue. Despite current setbacks, underlying segments like research services are showing growth, driven by increasing capacity utilization in both small and large molecules, along with a diversified business model and strong client relationships. Strategic investments in specialized facilities for high-potency compounds and advancements in biologics assay and fill-finish capabilities highlight Syngene's commitment to fortifying its R&D infrastructure and service diversification.

Over the past 52 weeks, Syngene International Ltd has traded between a low of ₹360.35 and a high of ₹678.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Syngene International Ltd has a market capitalization of approximately 15,246.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Syngene International Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 68.99 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 15,246.58 Cr, Syngene International Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Syngene International Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Syngene International Ltd is 68.99. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Consolidated revenue from operations in Q1 FY27 fell 16% year-on-year to Rs 736 crore. Standalone revenue from operations was reported at Rs 663 crore.

The 33rd AGM is scheduled for Wednesday, July 29, 2026 at 3:30 pm IST and will be held via VC/OAVM.

Syngene reported a consolidated net loss of Rs 9 crore for the quarter ended June 30, 2026.

Q4 FY26 revenue from operations was ₹1,036.5 crore, operating EBITDA was ₹303 crore with a 29% margin, and PAT before exceptional items was ₹153 crore. Reported PAT after exceptional items was ₹148 crore.